13F-HR: Pfizer Discloses Q4 2025 Equity Holdings
Institutional Holdings Report
Pfizer Inc. has filed its Form 13F-HR, revealing its equity holdings totaling over $236 million across 21 positions as of December 31, 2025.
Summary
- Pfizer Inc. submitted a 13F Holdings Report for the calendar quarter ended December 31, 2025.
- The report details 21 distinct equity security holdings.
- The total market value of these disclosed holdings amounts to $236,464,562.
- Significant holdings include ALLOGENE THERAPEUTICS INC with a value of $30,183,895, ARVINAS INC valued at $41,009,686, and ORIC PHARMACEUTICALS INC with a value of $43,978,494.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of equity holdings and does not contain performance metrics or forward-looking statements from the reporting entity.
Positives
- The filing provides transparency into Pfizer Inc.'s institutional investment activities and portfolio composition.
- It demonstrates active management of a diversified portfolio across 21 equity positions, primarily in the biotechnology and pharmaceutical sectors.
Negatives
- No specific negatives are directly discernible from this standard 13F filing, as it is a disclosure of holdings rather than an operational performance report.
Risks
- The market value of the disclosed equity holdings is subject to fluctuations based on overall market conditions, sector-specific trends, and the individual performance of the underlying companies.
- Investment in smaller biotechnology and pharmaceutical companies, as seen in the portfolio, typically carries higher volatility and specific development risks.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that institutional investment managers like Pfizer Inc. routinely file Form 13F-HR to disclose their equity portfolios. This filing provides insight into Pfizer's strategic investments, which appear concentrated in the biotechnology and pharmaceutical sectors, potentially reflecting venture capital activities, strategic alliances, or treasury management in areas complementary to its core business.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Assistant General Counsel | NA | Madelyn D. Purcell | 02-10-2026 | Signed the report on behalf of the reporting manager, not a change in management. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency into Pfizer's investment portfolio, offering insight into its strategic financial allocations and exposure to other companies.
- Investment Professionals: Offers data for tracking institutional investment trends, identifying potential investment opportunities, or analyzing portfolio shifts by major players like Pfizer.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 12-31-2025 | End of the calendar year/quarter for which the institutional holdings report is filed. |
| 02-10-2026 | Date the Form 13F-HR was signed and submitted to the SEC. |
Keywords
Pfizer, 13F, SEC filing, equity holdings, institutional investment, portfolio disclosure, biotechnology investments, pharmaceutical investments
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.